Recently, the CRISPR/Cas9 system has been used to correct the ASXL1 homozygous nonsense mutations that are present in the CML cell line KBM5, which lacks ASXL1 protein expression. Here, ASXL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.